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Nonenzymatic glycation of type IV collagen and matrix metalloprotein-
ase susceptibility. The glomerular basement membrane (GBM) is dam-
aged in diabetes through complex mechanisms that are not fully under-
stood. Prominent among them is nonenzymatic protein glycation leading
to the formation of so-called advanced glycation end products (AGEs).
We examined the effects of in vitro glycation of intact collagen type IV in
bovine lens capsule (LBM) and kidney glomerular (GBM) basement
membranes on their susceptibility to matrix metalloproteinases, using
stromelysin 1 (MMP-3) and gelatinase B (MMP-9). Sites of cleavage of
unmodified LBM collagen were located in the triple helical region. In vitro
glycation by glucose severely inhibited the release of soluble collagen
cleavage peptides by MMP-3 and MMP-9. The distribution of AGEs
within the three domains of collagen IV (7S, triple helical, and non-
collagenous NC1) were compared for LBM glycation using AGE fluores-
cence, pentosidine quantitation, and immunoreactivity towards anti-AGE
antibodies that recognize the AGE carboxymethyllysine (CML). Marked
asymmetry was observed, with the flexible triple helical domain having the
most pentosidine and fluorescent AGEs but the least CML. The in vivo
relevance of these findings is supported by preliminary studies of AGE
distribution in renal basement membrane (RBM) collagen IV domains
from human kidneys of two insulin-dependent diabetics and one normal
subject. Pentosidine and fluorescent AGE distributions of diabetic RBM
were similar to LBM, hut the CML AGE in diabetic kidney was less in the
triple helical domain than in NC1. Our results support the hypothesis that
nonenzymatic glycation of collagen IV contributes to the thickening of
basement membranes, a hallmark of diabetic nephropathy.
The glomerular basement membrane, which functions as a
molecular filtration device to selectively remove small molecules,
is damaged in diabetes through complex mechanisms that have
not been fully understood [1]. The elucidation of these mecha-
nisms is imperative, as no satisfactory therapy is currently avail-
able to prevent or treat the long-term complications of diabetes
[2]. The thin, sheet-like basement membrane structure is com-
posed mainly of type IV collagen, laminin, nidogen and proteo-
glycans [3, 4], components that play critical roles in cell adhesion,
tissue differentiation, and maintenance of tissue architecture [5].
The recent Diabetes Control and Complications Trial [61 provides
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strong support for the hypothesis that accelerated nonenzymatic
glycation is a central causative factor of diabetic nephropathy
[7—10]. Microvascular complications of hyperglycemia are likely to
arise from a direct modification of the long-lived collagen IV of
basement membranes. Circulating glycated plasma proteins, such
as albumin or immunoglobulins, can also be trapped through
cross-linking to the collagen of the kidney and probably contribute
to diabetic nephropathy [11—15]. Increased synthesis and de-
creased degradation of extracellular matrix components are other
important factors leading to the hallmark glomerular basement
membrane thickening observed early in this pathogenesis [16—21].
Collagen IV is the most abundant component of basement
membranes and forms the structural scaffolding on which other
proteins interact [3—6]. As illustrated in Figure 1, the collagen IV
molecule is a triple helical protomer composed of three chains. Six
unique alto a6 chains have now been identified in humans [22],
and their variable stoichiometric distribution within different
tissues (cf. [23]) is of much significance in normal and in certain
autoimmune diseases states. Two collagen IV protomers associate
in dimeric fashion at their carboxyl terminal globular NC1 do-
mains, while at their amino termini four protomers associate in an
antiparallel fashion to form the so-called 7S domain [24]. Span-
ning the two domains is an extended triple helical domain that
differs from fibrillar collagen in that it contains several distinctive
interruptions within the repeating Gly-X-Y sequences. These
interruptions are believed to provide important flexibility required
for specialized collagen IV function [221.
Although nonenzymatic glycation of connective tissue collagen
has been extensively studied [25—27], much less is known about
the structural and functional consequences of glucose-induced
alterations in basement membrane type IV collagen (cf. [28—33]).
The nonenzymatic glycation of proteins, including collagen, is
initiated by reversible Schiff base condensation of glucose with
amino groups, such as lysine side-chains, followed by a largely
irreversible rearrangement that yields ketoamine Amadori prod-
ucts [34]. Slow, irreversible and oxidative Maillard "browning"
reactions then ensue and lead to many reactive intermediates and
products that are collectively referred to as "AGEs" (advanced
glycation end products) [35, 36]. These highly heterogeneous
AGEs include fluorogenic products and cross-links [37]. The best
characterized "glycoxidative" AGEs [38, 39] are the acid-stable
pentosidine cross-link [40—421 and the non-fluorescent carboxy-
methyllysine (CML) (Fig. 2) [43]. A strong case has recently been
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Fig. 1. (Upper panels) Structure and assembly
of basement membrane type IV collagen from
protomer composed of three chains (middle
panel), each of which consists of three domains:
N-terminal 7S, triple helical with interruptions
(vertical bars), and C-terminal globular Nd.
(Lower panel) Schematic of approximate
location of major MMP-3 and MMP-9 cleavage
sites in 1(IV) and 2(IV) chains from LBM
determined in this study. Identified cleaved
sequences are shown above and below, with
arrows indicating the bonds.
made that the latter is probably the dominant [44], though not
only [45], immunoreactive epitope for anti-AGE sera. These
AGEs have proven to be increasingly important biomarkers of
Maillard modification of diabetic tissues, even though AGEs have
not yet been shown to be true causative factors in diabetes [37].
We have made use of these markers in the present study to follow
in vitro and in vivo AGE formation in type IV collagen of
basement membranes.
An important question arises as to whether glycation-induced
cross-linking and accumulation of AGEs within long-lived base-
ment membrane proteins, such as collagen IV, may also interfere
with normal tissue remodeling [16—21, 46]. Lysine modification
and covalent AGE cross-links within and between proteins may
render them less susceptible to enzymatic and chemical degrada-
tion [7, 47]. Zinc-dependent matrix metalloproteinases (MMPs),
such as collagenases (MMP-1, MMP-8 and MMP-13), gelatinases
(MMP-2 and MMP-9) and stromelysins (MMP-3 and MMP-10),
are the class of endoproteinases responsible as a whole for the
degradation of extracellular matrix components [48—50]. Since
MMPs are required for normal tissue remodeling during devel-
opment, wound repair and angiogenesis, it was particularly im-
portant to examine whether nonenzymatic glycation of the extra-
cellular matrix may render it less susceptible to degradation by
MMPs. If so, this could prove to be a significant mechanism for
the observed abnormal wound repair and renal basement mem-
brane thickening of diabetes.
We report here studies on the degradation of collagen IV by
MMP-3 and MMP-9 in glycated basement membranes of bovine
lens capsules (LBM), an attractive model since they consist of
more than 90% type IV collagen [51], and kidney glomeruli
(GBM). In marked contrast to native basement membranes, we
find that glycation greatly inhibits or prevents the release of
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Fig. 2. Chemical structures of two AGEs. (Left)
N-(carboxymethyl)lysine, an immunoreactive
that is not a cross-link. (Right) Pentosidine, the
acid-stable fluorescent Lys-Arg cross-link.
collagen IV degradation fragments following MMP treatment.
We also report in vitro studies on glycated whole LBM basement
membrane to elucidate which collagen IV domains are most
susceptible to formation of different advanced glycation end
products. The in vivo relevance of these findings is supported by
preliminary studies we have carried out on AGE domain distri-
bution in collagen IV of the renal basement membrane (RBM) of
human diabetic kidney samples. Our results provide strong sup-
port for the hypothesis that glycation of collagen IV of basement
membranes contributes to the thickening of basement mem-
branes, a characteristic feature found in diabetic nephropathy.
METHODS
Materials
Bacterial collagenase (CLPSA) was purchased from Worthing-
ton Biochemicals. Secondary antibody conjugates were obtained
from Dako Corp. Prestained protein markers were purchased
from Bethesda Research Laboratories. Chemicals used for elec-
trophoresis were purchased from BioRad. Bovine lenses were
purchased from Pd Freez Biologicals (Rogers, AR, USA). Bovine
kidneys were collected from a local slaughterhouse and kept
frozen until use. Human kidneys were obtained from the Midwest
Organ Bank (Kansas City, MO, USA), St. Frances Hospital
(Wichita, KS, USA) and the Veterans Administration Medical
Center (Kansas City, MO, USA). They were kept frozen until use.
The human kidney samples were as follows: one kidney (desig-
nated N) of one normal 43-year-old male (deceased from an
aneurism) serving as a control; one kidney (designated Dl)
obtained at transplant from a 41-year-old female insulin-depen-
dent (IDDM) diabetic (duration approximately 20 years) with
severe diabetic complications showing glomerular necrosis; and
one kidney (designated D2) obtained at autopsy from a young
male age 23 (deceased from complications unrelated to diabetes)
that was IDDM diabetic (duration approximately 10 years).
Preparation of native and glycated bovine LBM
Bovine anterior lens capsules were prepared according to the
method of Peczon, McCarthy and Merritt [52]. Glycation in vitro
was accomplished by suspending bovine lens in 0.4 M phosphate
buffered saline, pH 7.5 containing 1.5 M glucose and 0.05%
sodium azide. Two lenses per ml of solution were incubated for 30
to 40 days at 37°C.
Preparation of collagen IV from native bovine GBM
The preparation and isolation of renal glomerular basement
membrane was done according to the method of Freytag, Ohno
and Hudson [53]. The cortex from slightly frozen kidneys was
shaved into an ice-cold solution of 0.85% NaC1 containing pro-
tease inhibitors [diisopropylfiuorophosphate (DFP), N-ethylmale-
imide (NEM), e-aminocarproate and EDTA]. The shavings were
passed through a meat grinder and diluted with the above
solution. Glomeruli were separated from the homogenate by
sieving techniques [54] and were resuspended in ice-cold 1 M NaCI
containing protease inhibitors. They were then sonicated, at a
temperature maintained below 10°C, in three 10 minute bursts,
with five minute intervals to allow cooling. The suspension was
passed through a 200-mesh sieve and the filtrate was pooled by
sedimentation at low speed. GBM was separated after washing
several times in 1 M NaCl by 525 X g centrifugation at 4°C. NaC1
was removed by several washings with water and the GBM was
pelleted at 4°C by centrifugation then lyophilized and stored at
—20°C until use.
Isolation of renal blood membrane collagen domains from
human normal and diabetic kidneys
Isolation and preparation of renal RBM was done according to
methods used in this laboratory [55, 56]. The cortex was shaved
into an ice-cold solution of 0.85% sodium chloride containing a
mixture of protease inhibitors (DFP, NEM, c-aminocarproic acid
and EDTA) and was soaked for 30 minutes. The suspension was
ground in a blender and the slurry was centrifuged. The pellet was
suspended in ice-cold 1 M sodium chloride and 2000 units of
DNase I were added. Suspension was stirred at room temperature
for 1.5 hours and pelleted by centrifugation. The pellet was
resuspended in a solution of 2% deoxycholate containing 0.2%
sodium azide and stirred for four hours at room temperature. This
was then centrifuged and the pellet was washed with water three
times and frozen at —20°C or used immediately.
Digestion of glycated and native bovine lens capsule basement
membrane with MMP-3 or MMP-9
Glycated or native LBM (500 jig) was suspended in 500 jil of 50
mM Tris-HCI, pH 7.5 containing 1 m calcium chloride and 0.02%
sodium azide. MMP-3 and MMP-9 were purified as proenzymes
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Fig. 4. Analysis of MMP-9 degradation of native LBM using SDS-PAGE
with a 4 to 22% gradient of acrylamide and staining with Coomassie Blue.
LBM was digested for 24 hours at 37°C and the supernatant was analyzed
by PAGE (control of undigested LBM is included in Fig. 6 below).
Fragments at 27 kDa and 26 kDa stained positively in Western blots with
anti-NC1 antibodies.
helical region. This was passed over a BioSil TSK HPLC column
equilibrated with either 150 mrvi ammonium bicarbonate or am-
monium acetate, pH 7.0 or over Sephacryl S-300 gel. The 7S and
NC1 domains and the peptides released from the triple helical
region of collagen IV were collected from the column [59j and
lyophilized. Protein concentrations of the domains were obtained
from amino acid analyses of the different fractions. Approximate
molar concentrations were computed by assuming that the triple
helical, NCI and 7S domains contained 1288, 227 and 150
residues, respectively, with a mean residue weight of 110.
Quantitation of pentosidine
Fig. 3. Analysis of MMP-3 degradation of native lens basement mem-
brane (LBM) and glomerular basement membrane (GBM) using SDS-
PAGE with a 4 to 22% gradient of acrylamide. LBM and GBM were
digested for 24 hours at 37°C and the supernatants were analyzed by
PAGE (controls of undigested LBM are included in Fig. 6 below). (A)
Stained with Coomassie Blue showing molecular weight standards. (B)
Western blot using anti-NCI antibodies.
according to Nagase et al [57] and Morodomi et al [58], respec-
tively, and were activated with 1.5 m of the mercurial 4-
aminophenylmercuric acetate (APMA). An enzyme-to-substrate
ratio of 1:500 and 1:1000 (wt:wt) was used for MMP-3 and
MMP-9, respectively, and digestion proceeded at 37°C for various
times. The digestion was stopped by the addition of 50 itl of 150
mM EDTA and the samples were frozen until analysis.
Isolation of collagen IV domains from LBM, RBM and GBM
Native GBM or RBM and native or glycated LBM were treated
with bacterial collagenase (0.1% wt:wt) in a buffer of 150 mai
ammonium bicarbonate or ammonium acetate pH 7.4 containing
1 m calcium chloride and 0.02% sodium azide at 37°C for 18
hours. Undigested material was removed from the solution by
centrifugation, leaving supernatant containing 7S and NC1 do-
mains as well as liberated collagenous peptides from the triple
Pentosidine quantitation was done essentially according to the
method of Sell and Monnier [601. An authentic sample was
synthesized in our laboratory by the method of Sell and Monnier
[401. A standard curve was generated by running known quantities
of pentosidine on HPLC and measuring peak areas using pento-
sidine-specific fluorescence detection (335 nm excitation/385 nm
emission). Amino acid analysis was used to determine the protein
concentration of the collagen IV domains. Known amounts of
collagen IV domains were acid hydrolyzed in 6 N HC1 and
analyzed for pentosidine by HPLC chromatography on a Vydac
C-18 column using a TFAlacetonitrile gradient. Organic phase
was increased 0.2% per minute. Elution position and the amount
of fluorescence was compared to the pentosidine standard for
quantitation.
Electrophoresis, immunodetection and ELISA
SDS-PAGE electrophoresis and immunoblot analysis of colla-
gen were done according to Butkowski et al [61]. Antibodies to
the NCI domain of collagen IV were used as previously described
[61]. Rabbit polyclonal antibodies that recognize AGEs were
prepared following published work of others, as recently de-
scribed from this laboratory [62]. The AGE-BSA immunogen was
BSA that had been glycated for two months with glucose. ELISA
was done according to Engvall [63]. Subsequent to the completion
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Fig. 5. MMP-3 and MMP-9 cleavage sites
found within LBM collagen IV identified by
amino terminal sequencing of 35 kDa and 27
kDa fragments generated by MMP-3 and of 27
kDa and 26 kDa fragments generated by MMP-
9 (see also Fig. 1). Numbering in brackets
corresponds to 1(IV) and 2(JV) sequences
presented in Muthukumaran et al [811,
Hostikka and Tryggvason [821 and Pihiajaniemi
et al [83J.
of the experiments of this study, reports have appeared [44, 45]
that similar polyclonal anti-AGE antibodies primarily recognize
the carboxymethyllysine (CML) AGE (Fig. 2). We examined
whether this is true for the antibodies we used by passing our
antibodies on a column of immobilized BSA that had been
moderately carboxymethylated. All the AGE-recognizing anti-
body was adsorbed on the column [64], in apparent confirmation
that carboxymethyllysine is the major epitope recognized by our
anti-AGE antibodies.
Fluorescence detection of general AGE formation
General AGE formation was also monitored by Ex 370/Em 440
nm fluorescence that is the hallmark of protein glycation [65, 66].
The major fluorophore has yet to be identified despite several
attempts [67—721, presumably due to its acid lability. However, this
fluorescence has been the most commonly used single index of
formation of advanced glycation end products. Note that the
acid-stable pentosidine AGE fluorophore, which we also quanti-
tated, is present in extremely small amounts in glycated proteins
[37—421.
Amino acid composition analysis and sequencing
Amino acid composition analysis and sequencing were per-
formed by the Protein Microsequencing Facility in the Depart-
ment of Biological Chemistry at UCLA Medical Center. To
determine MMP-3 and MMP-9 cleavage sites, degradation end
products of collagen TV were separated by SDS-PAGE using a 4
to 22% acrylamide gradient, electrotransfered to PVDF paper
(Immobilon-P) and sequenced.
RESULTS
Cleavage products generated by MMP-3 and MMP-9 digestion
of native basement membrane
We first characterized the effects of MMP-3 and MMP-9 on
degradation of native collagen IV within an intact basement
membrane prior to glycation. Limited information is available
regarding the nature of degradation fragments produced by either
of these enzymes [73—75]. We first chose bovine anterior lens
capsule basement membrane (LBM) that is predominantly colla-
gen IV [51] for studies of degradation by MMP-3 and MMP-9. As
noted above, LBM collagen IV constitutes more than 90% of this
membrane, primarily only 1(IV) and 2(IV) chains with little
intermolecular disulfide cross-links. Limited parallel studies were
also carried out on GBM, which is considerably more complex and
heterogeneous in composition, and its collagen IV contains a
variety of chains [1(IV) to 6(IV)J that show extensive intermolec-
ular disulfide cross-links [22—26]. Digestion end products were
analyzed by SDS-PAGE protein staining (non-specific Coomassie
Blue) and NC1 immunoblot methods. Figure 3A demonstrates
that digestion of LBM and GBM with MMP-3 generates a series
of fragments ranging from 125 down to 15 kDa, in general
agreement with Bejarano et al [73]. Many of these fragments
reacted with antibodies raised against isolated NCI domain of
collagen IV (Fig. 3B), especially those at 69, 63, 56, 35 and 27
kDa. In comparison, Coomassie Blue staining of the digestion of
LBM with MMP-9 reveals two major degradation fragments of 27
and 26 kDa (Fig. 4), as well as minor fragments weakly visible at
approximately 40 kDa. All three of these MMP-9 generated
fragments reacted with antibodies to the NCI domain of collagen
IV (data not shown).
To identify the major cleavage sites within LBM collagen IV, six
fragments generated by MMP-3 (125 kDa, 89 kDa, 69 kDa, 63
kDa, 35 kDa and 27 kDa) and two fragments generated by
MMP-9 (26 kDa and 27 kDa) were subjected to amino acid
sequence analysis. As shown in Figure 5, amino acid sequences
obtained from 35 kDa fragment and the 27 kDa fragment
generated by MMP-3 digestion were found to match known
sequences of the human and murine 1(IV) chain and 2(IV) chain,
respectively. Based on the apparent molecular weights and their
reactivity with antibodies to the NC1 domain, these two fragments
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Fig. 6. Elfect of glycation on the degradation of LBM by MMP-3 (A and B) and MMP-9 (C and D) as followed by SDS-PAGE. Supernatants from
digestion and control samples were analyzed. Panels A and C are Coomassie Brilliant Blue staining. Panels B and D are immunoblot analyses using
antibodies raised against the isolated NC1 domain. Control represents tissue incubated for 72 hours in the absence of MMPs. G denotes glycated and
N denotes native non-glycated tissue.
most likely contain the entire NC1 domain of their respective
alpha (IV) chains.
Amino acid sequence analysis of four larger fragments from
MMP-3 digestion generated multiple signals for each residue.
However one major sequence, consisting of I-G-A-OHP-G-F-
OHP-G-D-R-G-E-OHP, occurred in each of the four fragments
analyzed. This sequence is characteristic of a collagen triple helix
where glycine appears at every third position, and hydroxyproline
(OHP) is present at several of the Y positions in the G-X-Y
repeats. Isoleucine was identified as the amino terminal residue,
which is consistent with MMP-3 specificity [761. Additionally,
amino acid analysis of these fragments suggested that they
contained large portions of the triple helical domain. The glycine
content approached 30% and a large amount of hydroxyproline
was observed (data not shown). These fragments also reacted with
NC1 antibody suggesting that the triple helical region was not
completely excised from the collagen IV molecule. Apparently
MMP-3 cleaves within the triple helical domain in such a way as
to retain some or all of the NC1 domain of the collagen IV
molecule.
The amino acid sequences obtained from the 27 kDa and 26
kDa fragments generated by MMP-9 matched the sequences of 2
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Fig. 7. Effect of glycation on the release of hydroxyproline by MMP-3 frt)
and MMP-9 (B) digestions of LBM. Symbols are: (•) native LBM; (A)
glycated LBM.
(IV) chain and 1 (IV) chain, respectively (Fig. 5). As with MMP-3
degradation, these two fragments were released by cleavage close
to the amino terminal region of the NC1 domain. The fragments
generated by MMP-9 most likely contained all of the NCI domain
based on their reactivity with NC1 antibodies and the apparent
molecular weights. Interestingly, the MMP-9 cleavage site that
generated the 27 kDa fragment was at the same position as the
MMP-3 cleavage site generating a 27 kDa fragment. A diagram of
the MMP-3 and MMP-9 cleavage sites is depicted in Figure 1
(lower panel). To summarize, both MMP-3 and MMP-9 cleave
collagen TV contained within a basement membrane at multiple
sites within the triple helical domain of collagen IV.
Glycation inhibits the release of collagen IV fragments from
LBM and GBM by MMP-3
While glycated proteins have been shown to be more resistant
to degradation by chemical or enzymatic treatment [25, 26], the
degradation of glycated collagen IV from basement membranes
by enzymes thought to be responsible for in vivo remodeling of the
extracellular matrix has not been evaluated. We first glycated
bovine LBM and GBM in vitro using 1.5 M glucose, as described
in the Methods section. Equal quantities of glycated and native
LBM or GBM were then treated with MMP-3 or MMP-9 for 24,
48 and 72 hours. Degradation fragments of native and glycated
collagen IV were analyzed by electrophoresis using Coomassie
7S NC1 Triple Helical
Fig. 8. Relative distribution of AGEs within domains of type IV collagen
of in vitro glycated LBM. (4) CML AGE was determined by ELISA using
anti-AGE antibodies; (B) Fluorescence determined at Ex 370/Em 440 nm
(general AGE; ) and Ex 330/Em 400 nm (pentosidine-rclated, ). (C)
Relative pentosidine content determined after HPLC separation. Equal
molar amounts of each domain, determined by amino acid analysis, were
used in the analysis.
staining (Fig. 6 A, C) and NCI immunoblot (Fig. 6, B, D) of the
digestion supernatant. Additionally, the amount of collagen IV
degradation was quantitated by the standard method of measur-
ing soluble hydroxyproline released into the digestion superna-
tant.
Figure 6 shows that degradation fragments were observed in the
native LBM samples at 48 hours, but no degradation fragments
were observed from the glycated LBM sample even after 72 hours
with either MMP-3 (top panel) or MMP-9 (bottom panel) diges-
tions. Analysis of hydroxyproline released into the digestion
supernatant correlated well with the electrophoresis results (Fig.
7). These results demonstrate that collagen IV within the glycated
LBM is not as susceptible to MMP 3 and MMP 9 as native LBM.
Parallel experiments were carried out with GBM preparation,
although the Coomassie staining did not provide information
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Fig. 9. Distribution of AGEs within domains of type IV collagen of RBM
isolated from IDDM diabetic (labeled Dl and D2) and normal kidneys
(labeled N). (A) CML AGE. (B) General AGEs determined by Ex 370/Em
440 nm fluorescence. (C) Pentosidine-related Ex 370/Em 440 nm fluores-
cence. (D) Relative pentosidine content determined after HPLC separa-
tion. Equal molar amounts of each domain, determined by amino acid
analysis, were used in the analysis.
specific for collagen IV due to the heterogeneity of the GBM
components. As with LBM, glycation completely inhibited the
release of MMP-3 cleaved collagen IV fragments for up to 72
hours of incubation, as judged by either nonspecific Coomassie
staining or with immunoblotting using anti-NC1 sera (data not
shown). In the case of MMP-9 digestion, glycation inhibited the
release of GBM fragments up to 48 hours, with faint bands
staining for NC1 appearing only at 72 hours of incubation (data
not shown).
Comparison of glycation-induced AGE formation within the
domains of intact LBM collagen IV
The formation of AGEs within collagen IV domains upon
glycation of intact LBM basement membranes was then exam-
ined. Collagen IV domains were solubilized from glycated and
native intact LBM using bacterial collagenase and were then
tested for the presence of various AGEs. Preliminary studies
established that bacterial collagenase was superior to several
other enzymes tested in solubilizing collagen IV domains from a
glycated basement membrane (unpublished observations). Solu-
bilized glycated LBM collagen IV showed a fivefold increase in
AGE-related fluorescence over controls (data not shown) at two
characteristic AGE fluorescence bands [661: pentosidine-like Ex
330/Em 400 nm and general AGE Ex 370/Em 440 nm. An
independent measure of AGE formation was obtained with
CML-specific anti-AGE antibody reactivity in an ELISA assay.
Solubilized glycated LBM collagen IV reacted with CML-specific
antibodies (raised against AGE-BSA), while control native solu-
bilized collagen IV did not (data not shown).
To determine AGE distribution within collagen IV, we isolated
the 7S and NCI domains, as well as the collagenase solubilized
peptides from the triple helical domain, by gel filtration chroma-
tography and analyzed them for AGE content. As shown in Figure
8A, both the 7S and the NC1 domains reacted with the CML-
specific antibody (raised against AGE-BSA), while peptides iso-
lated from the triple helical domain reacted only slightly. How-
ever, the triple helical peptides were highly enriched in the
pentosidine AGE as compared to the 7S and NC1 domain (Fig.
8C). It is notable that the Ex 370/Em 440 nm fluorescence (Fig.
8B) followed the distribution of pentosidine-like fluorescence (Ex
335/Em 400 nm) or that of HPLC-quantitated pentosidine (Fig.
8C), strongly suggesting that the unknown Ex 370/Em 440 nm
AGE fluorophore may also arise from the cross-linking of posi-
tively charged side-chains. Clearly, while AGEs are formed within
all three domains of collagen IV upon glycation of a basement
membrane, the distribution of different AGEs is apparently highly
asymmetric.
AGE distribution in vivo in collagen 1V domains of RBM from
diabetic patients
The availability of human kidneys from diabetic and control
subjects afforded a preliminary opportunity on low amounts of
tissue to also investigate the domain distribution of AGEs pro-
duced in vivo in collagen IV of RBM. Based on this very limited
material and samples, interesting differences and similarities were
evident in comparison to the in vitro glycated LBM collagen IV.
Figure 9A-C clearly show that the asymmetric distribution of the
AGE fluorophores seen with glycated LBM is also reflected in the
RBM of diabetic patients, with the triple helical domain again
showing a large excess of such cross-link derived AGEs. Remark-
ably, however, the non-cross-link CML AGE showed a slight
enrichment in only the NC1 domain as compared to the normal
kidney (Fig. 9A), with the total relative amount being approxi-
mately the same in the 7S and triple helical domains.
DISCUSSION
The initial focus of this study was the effects of nonenzymatic
glycation of intact basement membrane collagen, as occurs in
diabetic nephropathy, on its susceptibility to digestion by matrix
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metalloproteinases MMP-3 and MMP-9. Previous studies from
these laboratories have shown that MMP-3 releases soluble
collagen IV fragments from intact LBM and GBM basement
membranes [731. We chose LBM basement membranes as an
initial model in this work, since it is composed of more than 90%
collagen IV [51] in a classical 2:1 stoichiometry in 1 and 2 chains
with little intermolecular disulfide bonds. More limited parallel
studies were done on GBM, as it is considerably more heteroge-
neous in composition and its collagen IV contains a more diverse
set of 1(IV)-5(IV) chains with extensive interchain disulfide
cross-links [22, 23]. The marked effects of glycation on preventing
MMP degradation that we have seen (Fig. 6) has prompted us to
examine and compare the distribution of collagen IV advanced
glycation end products in GBM from human diabetic kidneys with
that of the LBM. To complete this study, we also examined the
sites of cleavage by MMP-3 and MMP-9 and the domain distri-
bution of preferred glycation sites in collagen IV of LBM.
The present work identifies several MMP cleavage sites in
intact basement membrane collagen that appear to contain the
intact NC1 domain, suggesting primary cleavage within the triple
helical region. Cleavage with the NC1 domain had been previ-
ously suggested [77], while others have reported cleavage near the
7S domain Fessler et al [78]. Under the conditions used here, it is
not possible to determine the first site of cleavage by MMP, and
determining the sequence of cleavages is beyond the scope of this
study. Nevertheless, the most notable finding of the present work
is that glycation of LBM and GBM strongly inhibits the release of
collagen IV degradation fragments from MMP digestion. No
soluble fragments could be detected from MMP-3 even after 72
hours of digestion (Fig. 6).
The inhibition of the release of cleaved fragments by glycation
could be due to a number of factors, including the formation of
AGE cross-links within individual collagen chains or between
adjacent chains. Fluorescence and anti-AGE antibody reactivity
clearly showed that extensive AGE formation occurred with
glucose (Fig. 8). However, it is important to note that the actual
number of additional collagen cross-links specifically formed by
glycation may be small, particularly those arising from fluorescent
cross-links [37—42]. Alternatively, glycation at lysine residues, as
reflected by formation of the carboxymethyllysine AGE detected
by our antibodies, could have rendered the collagen IV a poor
substrate for MMP cleavage through direct or indirect effects on
substrate binding or orientation, It has been noted that CML
formation is the major AGE and is at least 100-fold more
prevalent than pentosidine cross-link AGEs [37]. Regardless of
the precise mechanisms for these effects, the present results
indicate that glycation of basement membrane collagens is likely
to interfere significantly with their in vivo turnover and processing
during remodeling of tissues and organs.
Our results on the glycation of intact LBM demonstrate an
unusual asymmetrical distribution of AGEs within different do-
mains of collagen IV (Fig. 8). Since pentosidine is a cross-link
involving both lysine and arginine [40—42], its greater formation
within the triple helical domain of collagen IV suggests either
greater clustering of these positively charged side-chains or
greater flexibility for collagen-collagen association within the
triple helix. Since the immunoreactive AGEs are predominantly
the non-cross link carboxymethyllysine [44, 51, preferential for-
mation of the CML AGE in the 7S and NC1 domains may simply
reflect greater accessibility of lysine side-chains in these domains.
Our results are fully consistent with the recent findings of Raabe
et al [79] where the glycation of 7S and triple-helical domains was
carried out in solution after separating the domains, rather than
on intact basement membrane collagen. They found a much
greater fluorescence increase in the triple helical region compared
to the 7S domain. However, they did not carry out any studies on
the isolated NC1 domain. It is notable that the distribution of the
AGE fluorescence (Ex 370/Em 450 nm) parallels the distribution
of pentosidine-like fluorescence (Ex 335/Em 400 nm) among the
domains, suggesting that this dominant unknown AGE fluoro-
phore may also be a cross-link condensation product of two basic
side chains. Recent studies [69—72] have, indeed, identified novel
cross-linked lysine AGEs with similar, though not identical,
spectral and fluorescence properties.
The preliminary examination of the AGE domain distribution
profiles in the RBM type IV collagen of human diabetic kidneys
(Fig. 9) reveals important similarities and differences to those of
glycated LBM (Fig. 8). It is clearly evident that the distribution of
the fluorescent AGEs, including pentosidine, in the diabetic
patient follows that seen in the glycated LBM. However, the
immunoreactive CML AGE does not appear to do so and shows
a slight enhancement in the NC1 domain of the diabetic patient.
Despite the limited samples examined, the observed trends are
supportive of recent analyses of the mechanisms of formation of
these various AGEs. In particular, it has been emphasized that the
CML AGE can also arise from a variety of sources other than
glycation, such as lipoxidation, and is thus a measure of overall
oxidative stress arising from multiple sources [37, 80]. In contrast,
pentosidine is only known to arise from glycoxidative pathways,
making it a superior indicator of diabetic glycation processes [37].
The differences we see in the domain distribution of CML and
pentosidine in the diabetic samples versus the in vitro glycated
LBM samples may be a reflection of these fundamental differ-
ences of the two AGEs first noted by Baynes and co-workers.
In conclusion, our studies suggest that glycation greatly inhibits
the turnover and release of collagen IV of GBM and LBM
basement membranes. The mechanisms by which this occurs
remain to be determined. The similarity and differences in the
formation of AGEs in type IV collagen of in vitro glycated LBM
and in human RBM of diabetic patients suggest that nonenzy-
matic collagen IV glycation may be an integral factor in the
development of vascular and renal pathogenesis in diabetes.
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APPENDIX
Abbreviations are: AGEs, advanced glycation end products; LBM,
bovine lens capsule basement membrane; GBM, glomerular basement
membrane; MMP, metalloproteinase; CML, carboxymethyllysine; RBM,
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renal basement membrane; DFP, diisopropylfiuorophosphate; NEM, N-
ethylmaleimide.
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